Phase I Clinical Trial of Recombinant Adenovirus Type 5 Therapeutic AIDS Vaccine Expressing Gag
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Acquired Immunodeficiency Syndrome
- Sponsor
- Centers for Disease Control and Prevention, China
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- Occurrence, intensity and relationship to vaccination of local and systemic adverse events
- Last Updated
- 10 years ago
Overview
Brief Summary
This is a randomized, double-blind placebo-controlled dose-escalation clinical trial to evaluate the safety and the immunogenicity of Adenoviral vector 5 HIV-1 vaccines in subjects receiving stable highly active antiretroviral therapy(HAART) .
Detailed Description
Patients continue antiretroviral medications throughout the course of this study. Three groups of patients receive dose-escalation (2×10\^9VP, 2×10\^10VP or 2×10\^11VP) injections of Adenovirus vector vaccine (Ad5-gag). Two weeks post immunization of lower dose, if the vaccine is safe and well tolerant, the next dose of immunization will begin. patients are monitored for safety 72 hours after each immunization. In addition, each patient records adverse events in a diary. Patients have regular physical exams, pregnancy tests, and blood drawn for virologic and immunologic assessments. The induction of HIV-specific responses will be measured.
Investigators
Yi Zeng
Yi Zeng, Departement Director, Centers for Disease Control and Prevention, China
Centers for Disease Control and Prevention, China
Eligibility Criteria
Inclusion Criteria
- •Are willing to participate this study and available for follow-up for the duration of the study.
- •Men and women aged 18-50 years.
- •Are HIV-positive.
- •Have been taking stable anti-HIV drugs for at least 6 months.
- •CD4 count ≥ 350 cells/mm3
- •Plasma viral load \< 50 copies/ml.
- •Willing to use acceptable forms of contraception at least 21 days prior to first vaccination until 56 days after the last vaccination.
Exclusion Criteria
- •Pregnancy or breast-feeding.
- •History of previous vaccination with an HIV-1 vaccine.
- •Use of immunoinhibitory agents, such as corticosteroids or cytotoxic drugs by oral administration, injection route or inhalation route within 6 months of study entry (But corticosteroids used for allergic rhinitis and skin topical application of corticosteroids were not included); Use of immunomodulatory agents including but not limited to interleukin-2(IL-2） and granulocyte-macrophage colony-stimulating factor (GM-CSF) within 30 days of study entry.
- •Use of blood products within 3 months of study entry.
- •Use of other experimental drugs within 3 months of study entry.
- •Any immunization within 3 months of study entry.
- •Comply with any of the following items： Active pulmonary tuberculosis； History of serious adverse reaction to other vaccines； Serious asthma； Have untreated thyroid disease; Syphilis
- •Laboratory values（Comply with any of the following items）:
- •Hemoglobin \< 100 g/L (male subjects)，\<90 g/L (female subjects)； Absolute neutrophil count ≤ 1000 cells/mm3； Serum creatinine ≥15 mg/L，endogenous creatinine clearance rate \<50 ml/min； alanine aminotransferase（ALT）, aspartate aminotransferase(AST) ≥3× upper limit of normal range； Total bilirubin ≥2× upper limit of normal range
- •Clinically significant electrocardiogram changes.
Outcomes
Primary Outcomes
Occurrence, intensity and relationship to vaccination of local and systemic adverse events
Time Frame: 12 months
To evaluate the safety and tolerance of a replication defective adenovirus expressing HIV-1 gag in HIV-1 infected subjects on highly active antiretroviral therapy.
Secondary Outcomes
- Immunogenicity of vaccine(24 month)